| アブストラクト | OBJECTIVE: We analyze and identify the signals of gender differences in adverse events (ADEs) related to Osimertinib and provide reference for clinical implementation of individualized drug use. METHODS: ADE reports of Osimertinib received from FAERS database from the first quarter of 2016 to the fourth quarter of 2022 were extracted. Reporting odds ratio (ROR) data analysis strategy was used for mining of signal strength that represents gender differences in ADEs related to Osimertinib. RESULTS: The number of Osimertinib ADE reports included in the analysis was 7968 in females and 7570 in males, respectively. According to ROR, men were more likely to develop pneumonia aspiration, lung infection, interstitial lung disease, pulmonary toxicity, dyspnea, ventricular extrasystoles, and pulmonary thrombosis, while women were more likely to develop cardiac failure congestive, stomatitis, diarrhea, muscle spasms, nail disorder, onycholysis, skin disorder, dry skin, and rash. CONCLUSION: Gender differences existed in ADE signals related to Osimertinib. The higher risk of ADEs in male patients was lung diseases that seem more serious than those nail toxicities or skin problems that occurred in female patients. In order to ensure the safety of medication, we should be alert to the differences between different genders and take corresponding preventive measures to reduce the occurrence of serious ADEs. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2023/7/29 |
|---|
| 投稿者 | Li, Zhiping; Zou, Wenbin; Yuan, Jiao; Zhong, Yunxiang; Fu, Zhiwen |
|---|
| 組織名 | Department of Pharmacy, Dongguan Binhaiwan Center Hospital, Dongguan, China.;Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong;University of Science and Technology, Wuhan, China.;Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37515501/ |
|---|
